Assertio Sells INDOCIN, SPRIX, SYMPAZAN to Cosette for $35M

Assertio Holdings has entered into an asset purchase agreement with Cosette Pharmaceuticals to sell Assertio’s remaining rights in INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR and the decommercialized OTREXUP. The upfront consideration is $35.0 million in cash.

The agreement also includes potential additional deferred payments. These include future milestone payments up to $32.0 million tied to sales milestones for SYMPAZAN, OTREXUP and INDOCIN, plus SPRIX-related contingent payments: $1.0 million for successful quality approval and batch delivery by May 31, 2026, an 8% share of gross profits from SPRIX from April 8, 2026 through December 31, 2027, and a $2.0 million payment if 2027 calendar-year net sales of SPRIX exceed $7.0 million.